Category: News
-
New Swiss alliance to improve cell therapy manufacturing
The industry-academia partnership of Bracco Imaging, Limula, and the University of Fribourg aims to revolutionize how life-saving ‘living drugs’ are made.
-
RapidAI wins FDA nod for five new AI tools
RapidAI bolsters its clinical AI platform with new FDA-cleared modules designed to enhance neurology, vascular, and radiology care.
-
Circio bolsters data for circVec circular RNA expression platform
New data shows enhanced performance in heart and brain tissues, broadening the platform’s therapeutic potential and boosting gene expression by 50%.
-
Levron Medical emerges with new approach to treating heart failure
Following first-in-human results and new funding, the company prepares for a clinical study at Sheba Medical Center.
-
Sorcero raises $42.5 million for AI adoption in life sciences
The company plans to use the new investment to scale its AI platform and expand applications across global pharmaceutical and medical device sectors.
-
Voio emerges from stealth, launches AI for medical scans
The company has $8.6 million in funds, with the Pillar-0, an open-source AI model developed by UC Berkeley and UCSF.
-
Telix bolsters data for PET imaging agent, helps optimize treatment
ZIRCON-X study shows Telix Pharmaceuticals’ Zircaix changes help reduce unnecessary invasive procedures in patients with indeterminate renal masses.
-
FDA expands Grifols’ antithrombin therapy in children
The US regulator approves expanded Thrombate III label, offering new treatment options for children with hereditary antithrombin deficiency.
-
Rapid Nexus earns FDA clearance for first wound healing device
California med-tech firm Rapid Nexus secures FDA clearance for Hemastyl, a device targeting the root cause of chronic non-healing wounds.
-
UK launches nuclear-driven push into precision cancer medicine
Recycled nuclear materials to fuel next-generation targeted alpha treatments in a major UK initiative.
-
Amgen’s new data reinforce weight regain after GLP-1 discontinuation
Amgen’s exec and study’s author explain that data shows stopping GLP-1s leads to weight regain, while managing LDL-C significantly reduces cardiovascular event risk.
-
Adagene & Third Arc Bio forge $845 million T-cell engager pact
Adagene licenses its SAFEbody tech to Third Arc Bio for two masked CD3 T cell engagers, netting $5million upfront, and upto $840 million in milestone payments.
Latest posts
-
Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
The risks and rewards of biomarker-based surrogates are crucial for optimizing clinical trial outcomes and guiding effective treatments.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Promis reports first human evidence of aβ oligomer reduction by pmn310
PMN310 demonstrates dose-dependent reduction of amyloid-beta oligomers in human CSF, marking a key milestone in Alzheimer’s treatment development.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.